Literature DB >> 15596639

Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.

Sergio Siragusa1, Raffaela Anastasio, Camillo Porta, Francesco Falaschi, Stefano Pirrelli, Piernicola Palmieri, Gabriella Gamba, Katerina Granzow, Alessandra Malato, Viviana Minardi, Paola Tatoni, Maria Antonietta Bressan, Guglielmo Mariani.   

Abstract

BACKGROUND: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined.
METHODS: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-dose treatment of LMWH; the remaining patients were discharged without anticoagulant administration. However, all patients were scheduled to undergo objective tests for DVT or PE within 72 hours. Standard antithrombotic therapy was administered when deferred diagnostic tests confirmed venous thromboembolism.
RESULTS: In total, 409 consecutive patients with suspected DVT and 124 with suspected PE were included in this study. A total of 23.8% (95% confidence interval [CI], 20.3%-27.3%) of patients had confirmed venous thromboembolism. At the short-term follow-up (72 hours), only a single thromboembolic event (0.2%; upper 95% CI, 0.6%) had occurred, whereas at the 3-month follow-up, 5 events (1.2%; 95% CI, 0.2%-2.1%) had occurred in patients in whom diagnosis of DVT or PE had previously been ruled out. None of the patients had major bleeding events. Ninety percent of patients were treated as outpatients.
CONCLUSION: Our study demonstrates that this approach allows the safe deferral of diagnostic procedures for DVT and PE for up to 72 hours.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596639     DOI: 10.1001/archinte.164.22.2477

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

Review 1.  D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism.

Authors:  Sergio Siragusa
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

2.  When pre-test probability can be deceptive.

Authors:  Micaela La Regina; Maria Cristina Pierantoni; Massimo Ratti; Francesco Orlandini
Journal:  Intern Emerg Med       Date:  2010-02       Impact factor: 3.397

3.  Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis.

Authors:  Synne G Fronas; Anders E A Dahm; Hilde S Wik; Camilla T Jørgensen; Jostein Gleditsch; Nezar Raouf; René Holst; Frederikus A Klok; Waleed Ghanima
Journal:  Blood Adv       Date:  2020-06-09

4.  Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism.

Authors:  Maddie S Stephen; Lana Castellucci; Marc Carrier; Lisa Duffett; Gregoire Le Gal; Marc Rodger; Philip S Wells; Aurélien Delluc
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

5.  Point-of-care multiorgan ultrasonography for the evaluation of undifferentiated hypotension in the emergency department.

Authors:  G Volpicelli; A Lamorte; M Tullio; L Cardinale; M Giraudo; V Stefanone; E Boero; P Nazerian; R Pozzi; M F Frascisco
Journal:  Intensive Care Med       Date:  2013-04-13       Impact factor: 17.440

6.  D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism.

Authors:  D Imberti
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.